CompanyEVMNNYSEPalo Alto, CA

Evommune, Inc.

Evommune develops therapies targeting chronic inflammatory diseases.

SEC EDGAR ClinicalTrials.gov evommune.com

8-KOct 1Latest SEC filing

Oct 1Latest story

October 2026

Evommune reports Phase 2a data for EVO301 in atopic dermatitis at EADV

Oct 1Clinical readoutEvommune, Inc.

September 2026

Evommune to present Phase 2a EVO301 atopic dermatitis data at EADV 2026

Sep 23Clinical readoutEvommune, Inc.

Evommune's EVO756 fails Phase 2b atopic dermatitis trial, shifts focus to EVO301

Sep 8Clinical readoutEVO756 Evommune, Inc.

August 2026

Evommune reports Q2 2026 results, sets EVO756 AD data for September

Aug 6Quarterly updateEVO756 Evommune, Inc.

July 2026

Evommune doses first patient in Phase 2b trial of EVO756 for migraine prevention

Jul 30Clinical readoutEVO756 Evommune, Inc.

June 2026

Evommune's EVO756 fails primary endpoint in Phase 2b urticaria trial

Jun 29Clinical readoutEVO756 Evommune, Inc.